Navigation Links
Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema

Company anticipates second quarter BLA filing for C1-inhibitor replacement therapy

NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. (Lev) today announced positive results from its pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH) for the acute treatment of hereditary angioedema (HAE). In the acute study, which is part of the company's CHANGE trials (C1-inhibitor in Hereditary Angioedema Nanofiltration Generation evaluating Efficacy), the protocol-defined primary endpoint was reached, showing a clinically and statistically significant reduction in the time to sustained relief of acute HAE symptoms. Based on the positive results of this study, the Company intends to submit a Biologics License Application to the Food and Drug Administration in the second quarter of 2007. HAE, or hereditary C1-inhibitor deficiency, is a rare and life-threatening inflammatory condition for which there is currently no FDA-licensed acute therapy in the United States.

In the double-blind study, which was conducted at 20 medical centers in the United States, a total of 71 patients were randomized to either C1-INH or placebo. The primary endpoint was met using the protocol-defined intent to treat analysis, with a median time to sustained symptom relief of 2.0 hours for patients receiving C1-INH compared to greater than four hours, the maximum evaluation period, for patients receiving placebo (p=0.026). Sustained symptom relief was defined as subject-reported symptom relief at three consecutive 15 minute intervals following treatment.

"I'm very pleased with the successful outcome of the CHANGE study for the acute treatment of HAE, and I'm hopeful that this will lead to the much-needed availability of C1-inhibitor therapy for this underserved patient population," said Bruce Zuraw, M.D., Professor of Medicine at the University of California San Diego and Principal Investigator of the Ph
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 29 Zeltiq Aesthetics, a science-based medical device company dedicated ... unwanted fat tissue, has announced the appointment of Gordie ... Mitch Levinson, the founder of Zeltiq Aesthetics, who served as ... a member of the Board of Directors since 2006. ...
... Misonix, Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... release fourth quarter and fiscal year ended June 30, ... Michael A. McManus, President and Chief Executive Officer ...
Cached Medicine Technology:Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... a person loses a large amount of blood the consequences ... have to be kept available in hospitals and blood banks. ... villages and conducting blood donation sessions in a laboratory bus. ... taken contain pathogens, including HIV, hepatitis and syphilis. As these ...
... 1 , Watch4net,s Testimonial , ... healthcare providers in terms of limited personnel and budget ... Health. An industry typically marked by growth is starting ... level executives are being tasked to run leaner organizations ...
... Two-thirds of women with psoriasis say the disease ... PORTLAND, Ore., Oct. 1 Women with psoriasis and ... suffer from the emotional and psychological effects of the ... Psoriasis Foundation today. , Psoriasis is the most prevalent ...
... ... for life science careers and information, unveiled the eleventh edition of the Biotech Beach™ ... ... resource for life science careers and information, unveiled the eleventh edition of the Biotech ...
... ... University Edwardsville School of Pharmacy has launched a new Web site: www.pharmacypainsummit.com , ... pharmacy. , ... IL (PRWEB) October 1, 2009 -- The Southern Illinois University Edwardsville School of ...
... Oct.1 issue of the journal Sleep shows that ... consistently report that their sleep is shorter and poorer. ... all of the subjective measures, including a 13.2 minute shorter ... (SOL), and a 4.2 percent lower sleep efficiency. When sleep ...
Cached Medicine News:Health News:Blood diagnosis -- chip-based and mobile 2Health News:Clarian Health Selects Watch4net for Performance Reporting and Automatic Analysis 2Health News:Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 2Health News:Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 3Health News:BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 2Health News:SIUE School of Pharmacy Launches Collaborative Site for Pain, Palliative Care Pharmacy 2Health News:SIUE School of Pharmacy Launches Collaborative Site for Pain, Palliative Care Pharmacy 3Health News:Study shows that elderly women sleep better than they think, men sleep worse 2
... a fully threaded 2.4 mm diameter titanium suture ... predrilling using either a powered handpiece or manually ... This implant is ideal for Bankart and SLAP ... with very high pull-out strengths. FASTak anchors are ...
... one step fixation of soft tissue to bone. ... cuff repair in one simple insertion maneuver. The ... of 5 mm and a small 2 mm ... hold a thin, bioabsorbable PLLA disc 5 mm ...
... Needles are ideal for arthroscopic suture passing ... are preloaded on one end of each ... As the anchor is being inserted, ensure ... tissue before removing the handle to ensure ...
... a 3 mm x 14 mm bioabsorbable threaded ... shoulder, knee, elbow and ankle. The exclusive braided ... of the anchor and provides superior resistance to ... unique eyelet design allows the attached suture to ...
Medicine Products: